Needham & Company Starts AtriCure Inc. (ATRC) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Tech stocks pull Wall Street lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Dougherty & Co Starts AtriCure Inc. (ATRC) at Buy
March 11, 2015 6:52 AM EDTDougherty & Co initiates coverage on AtriCure Inc. (NASDAQ: ATRC) with a Buy rating and a price target of $25.00. Analyst Charley Jones noted accelerating growth, and he thinks the company is likely to be acquired.
"ATRC is the technology and market share leader of the surgical atrial fibrillation (AF) and Left Atrial Appendage (LAA) markets, which we estimate will grow... More
